Projected return on investment in pharma research and development (R&D) in 2024 has risen to 5.9%, continuing the upward ...

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

The Simulation CoE is newly integrated into existing Deloitte Experience Centers to offer clients immersive experiences, ...

Deloitte is making strides to become a key player in the space industry for government and commercial services.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Deloitte Touche Tohmatsu India LLP has entered into a strategic alliance with Zoho, a global technology company, aiming to accelerate digital tra ...

Deloitte, in a series of annual reports on "Measuring the return from pharmaceutical innovation," in collaboration with other member firms, has provided insights into the state of biopharma R&D ...

NEW YORK, March 25, 2025 /PRNewswire/ -- Deloitte today announced the significant scaling of its Global Artificial Intelligence (AI) Simulation Center of Excellence (CoE), building on its global ...